Symptom severity and exacerbation frequency in medically treated patients with acromegaly
Authors' conclusion
In patients with acromegaly treated with injected depot SRLs, symptom exacerbations occurred frequently. Symptom severity and exacerbation frequency were associated with impaired daily functioning and reduced life satisfaction.
Study context
- Population
- Patients with acromegaly receiving injected depot somatostatin receptor ligands (SRLs); mean (SD) age 53.4 (13.6) years; 24 (77.4%) female; 15 (48.4%) on SRL monotherapy, 16 (51.6%) on SRL plus non-SRL therapyanalysis population
- Participants
- 31 patients
- Outcome
- Symptom exacerbation: ≥ 2-point increase in any symptom score (0-10 scales), current 2-day vs prior 2-day average
- Follow-up
- 3 months
Methodological detailsdaily 24-hour recall surveys for 3 months
- Daily 24-hour recall surveys for 3 months
Main finding
As reported in the abstract
Symptom exacerbations (daily surveys) · throughout the injection cycle
Days with symptom exacerbation, on average (> 2 days/week)
32.1%
Observational data: associations, not effects.
Further findings
3-month recall vs daily ratings
- Three-month recall overestimated symptom severity relative to daily ratings and did not capture exacerbation frequency
Life interference
- Greater symptom severity and exacerbation frequency related to impaired daily activities, reduced work productivity, treatment satisfaction and life satisfaction, and increased healthcare resource utilization (HCRU)
Original publication
Symptom severity and exacerbation frequency in medically treated patients with acromegaly. Pituitary. Published 23 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →